Aromatase, Breast cancer, Metastatic, Phase II, Postmenopausal, Vorozole,
Anti-Cancer Drugs
Department of Medical Oncology

Paridaens, R, Roy, J.A, Nooij, M.A, Klijn, J.G.M, Houston, S.J, Beex, L.V, … Piccart, M.J. (1998). Vorozole (Rivizor(TM)): An active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Anti-Cancer Drugs, 9(1), 29–35. doi:10.1097/00001813-199801000-00003